Pub Date : 2009-10-01Print Date: 2009-01-01DOI: 10.4137/oed.s2746
Sudha Nallasamy, Stefanie L Davidson, Lori J Howell, Holly Hedrick, Alan W Flake, Timothy M Crombleholme, N Scott Adzick, Terri L Young
Background: Fetal surgery is selectively offered for severe or life-threatening fetal malformations. These infants are often born prematurely and are thus at risk for retinopathy of prematurity (ROP). It is not known whether fetal surgery confers an increased risk of developing severe ROP relative to published rates in standard premature populations ≤37 weeks of age grouped by birth weight (<1500 grams or ≥1500 grams).
Design: This is a retrospective chart review.
Methods: We reviewed the charts of 137 patients who underwent open fetal/fetoscopic surgery from 1996-2004. Surgical indications included twin-twin transfusion syndrome (TTTS), myelomeningocele (MMC), congenital diaphragmatic hernia (CDH), sacrococcygeal teratoma (SCT), cystic adenomatoid malformation of the lung (CCAM), and twin reversed arterial perfusion sequence (TRAP). Of these, 17 patients had local ROP examination data. Binomial tests were performed to assess whether rates of ROP in our fetal/fetoscopic surgery cohort were significantly different from published rates.
Results: There were 5 patients each with an underlying diagnosis of TTTS and MMC, 2 patients each with CDH and TRAP, and 1 patient each with SCT, CCAM, and mediastinal teratoma. The mean gestational age at surgery was 23(4)/7 ± 2(3)/7 weeks, mean gestational age at birth was 30 ± 2(5)/7 weeks, and mean birth weight was 1449 ± 510 grams (610-2485). Compared to published rates of ROP and threshold ROP, our fetal surgery patients had significantly higher rates of ROP and threshold ROP in both the <1500 grams and the ≥1500 grams group (all p-values < 0.05).
Conclusions: Fetal/fetoscopic surgery appears to significantly increase the rate of ROP and threshold ROP development. Greater numbers are needed to confirm these observations.
{"title":"The effects of fetal surgery on retinopathy of prematurity development.","authors":"Sudha Nallasamy, Stefanie L Davidson, Lori J Howell, Holly Hedrick, Alan W Flake, Timothy M Crombleholme, N Scott Adzick, Terri L Young","doi":"10.4137/oed.s2746","DOIUrl":"https://doi.org/10.4137/oed.s2746","url":null,"abstract":"<p><strong>Background: </strong>Fetal surgery is selectively offered for severe or life-threatening fetal malformations. These infants are often born prematurely and are thus at risk for retinopathy of prematurity (ROP). It is not known whether fetal surgery confers an increased risk of developing severe ROP relative to published rates in standard premature populations ≤37 weeks of age grouped by birth weight (<1500 grams or ≥1500 grams).</p><p><strong>Design: </strong>This is a retrospective chart review.</p><p><strong>Methods: </strong>We reviewed the charts of 137 patients who underwent open fetal/fetoscopic surgery from 1996-2004. Surgical indications included twin-twin transfusion syndrome (TTTS), myelomeningocele (MMC), congenital diaphragmatic hernia (CDH), sacrococcygeal teratoma (SCT), cystic adenomatoid malformation of the lung (CCAM), and twin reversed arterial perfusion sequence (TRAP). Of these, 17 patients had local ROP examination data. Binomial tests were performed to assess whether rates of ROP in our fetal/fetoscopic surgery cohort were significantly different from published rates.</p><p><strong>Results: </strong>There were 5 patients each with an underlying diagnosis of TTTS and MMC, 2 patients each with CDH and TRAP, and 1 patient each with SCT, CCAM, and mediastinal teratoma. The mean gestational age at surgery was 23(4)/7 ± 2(3)/7 weeks, mean gestational age at birth was 30 ± 2(5)/7 weeks, and mean birth weight was 1449 ± 510 grams (610-2485). Compared to published rates of ROP and threshold ROP, our fetal surgery patients had significantly higher rates of ROP and threshold ROP in both the <1500 grams and the ≥1500 grams group (all p-values < 0.05).</p><p><strong>Conclusions: </strong>Fetal/fetoscopic surgery appears to significantly increase the rate of ROP and threshold ROP development. Greater numbers are needed to confirm these observations.</p>","PeriodicalId":74362,"journal":{"name":"Ophthalmology and eye diseases","volume":"1 ","pages":"13-9"},"PeriodicalIF":0.0,"publicationDate":"2009-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/oed.s2746","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31585867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The aim of this study was to characterize the affinity and permeability patterns of the amino acid ester prodrugs of acyclovir (ACV), L-alanine-ACV (AACV), L-serine-ACV (SACV), L-serine-succinate-ACV (SSACV) and L-cysteine-ACV (CACV) on rabbit primary corneal epithelial cell culture (rPCEC) and on rabbit cornea. Amino acid prodrugs of acyclovir, AACV, SACV, SSACV and CACV were synthesized in our laboratory. Chemical hydrolysis in aqueous buffer, enzymatic hydrolysis in corneal homogenates and transport across freshly excised rabbit cornea of these prodrugs were studied. SSACV inhibited the uptake of [3H] L-alanine on rPCEC and across the intact rabbit cornea. Lineweaver-Burk plot transformation revealed competitive inhibition between L-alanine and SSACV. In corneal tissue homogenate, the half lives of SSACV, SACV and CACV (t1/2) were observed to be 3.5 ± 0.4, 9.2 ± 0.6 and 1.8 ± 0.1 hr respectively, whereas AACV was readily converted to the active parent drug acyclovir exhibiting complete degradation before 5 min. Interestingly translocation of SACV across cornea was inhibited in the presence of 5 mM arginine (∼51%), a specific substrate for cationic transport system and in presence of BCH (∼38%), a substrate specific for large neutral amino acid transport system (LAT) or cationic and neutral amino acid transport system (B0,+). SACV exhibited higher permeability across cornea along with excellent antiviral activity against herpes simplex virus (HSV-1) and varicella-zoster virus (VZV) in comparison to ACV. Recognition by multiple transporters, stability in corneal homogenate and changes in physico-chemical properties contributed to the increased permeability of SACV across cornea.
{"title":"Small Neutral Amino Acid Ester Prodrugs of Acyclovir Targeting Amino Acid Transporters on the Cornea: Possible Antiviral Agents Against Ocular HSV-1 Infections.","authors":"K. Suresh, Xiadong Zhu, Talluri S. Ravi, A. Mitra","doi":"10.4137/OED.S0","DOIUrl":"https://doi.org/10.4137/OED.S0","url":null,"abstract":"The aim of this study was to characterize the affinity and permeability patterns of the amino acid ester prodrugs of acyclovir (ACV), L-alanine-ACV (AACV), L-serine-ACV (SACV), L-serine-succinate-ACV (SSACV) and L-cysteine-ACV (CACV) on rabbit primary corneal epithelial cell culture (rPCEC) and on rabbit cornea. Amino acid prodrugs of acyclovir, AACV, SACV, SSACV and CACV were synthesized in our laboratory. Chemical hydrolysis in aqueous buffer, enzymatic hydrolysis in corneal homogenates and transport across freshly excised rabbit cornea of these prodrugs were studied. SSACV inhibited the uptake of [3H] L-alanine on rPCEC and across the intact rabbit cornea. Lineweaver-Burk plot transformation revealed competitive inhibition between L-alanine and SSACV. In corneal tissue homogenate, the half lives of SSACV, SACV and CACV (t1/2) were observed to be 3.5 ± 0.4, 9.2 ± 0.6 and 1.8 ± 0.1 hr respectively, whereas AACV was readily converted to the active parent drug acyclovir exhibiting complete degradation before 5 min. Interestingly translocation of SACV across cornea was inhibited in the presence of 5 mM arginine (∼51%), a specific substrate for cationic transport system and in presence of BCH (∼38%), a substrate specific for large neutral amino acid transport system (LAT) or cationic and neutral amino acid transport system (B0,+). SACV exhibited higher permeability across cornea along with excellent antiviral activity against herpes simplex virus (HSV-1) and varicella-zoster virus (VZV) in comparison to ACV. Recognition by multiple transporters, stability in corneal homogenate and changes in physico-chemical properties contributed to the increased permeability of SACV across cornea.","PeriodicalId":74362,"journal":{"name":"Ophthalmology and eye diseases","volume":"2 1","pages":"43-56"},"PeriodicalIF":0.0,"publicationDate":"2009-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70712398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Preethi S Ganapathy, Penny Roon, Tracy K V E Moister, Barbara Mysona, Sylvia B Smith
Hyperhomocysteinemia has been implicated in visual dysfunction. We reported recently that mice with endogenous hyperhomocysteinemia, due to mutation of the cystathionine-β-synthase (cbs) gene, demonstrate loss of neurons in the retinal ganglion cell (RGC) layer and other retinal layers as homocysteine levels increase. Some clinical studies implicate hyperhomocysteinemia in the pathogenesis of diabetic retinopathy, which is also characterized by RGC loss. The present study used cbs(+/-) mice to determine whether modest elevation of plasma homocysteine, in the presence of diabetes, accelerates neuronal cell loss. Diabetes (DB) was induced in 3 wk old cbs(+/-) and wildtype mice using streptozotocin; four groups of mice were studied: DB cbs(+/-); non-DB cbs(+/-); DB cbs(+/+); non-DB cbs(+/+). One group of diabetic cbs(+/-) mice was maintained on a high methionine diet (HMD, 0.5% methionine drinking water) to increase plasma homocysteine slightly. Eyes were harvested at 5, 10 and 15 weeks post-onset of diabetes; retinal cryosections were examined by light microscopy and subjected to systematic morphometric analysis. Diabetic cbs(+/-) had significantly fewer RGCs at 5 weeks compared to age-matched, non-diabetic cbs(+/-) and wildtype controls (10.0 ± 0.5 versus 14.9 ± 0.5 and 15.8 ± 0.6 cells/100 µm retina length, respectively). Significant differences in retinas of DB/high homocysteine versus controls were obtained 15 wks post-onset of diabetes including fewer RGCS and decreased thickness of inner nuclear and plexiform layers. Moderate increases in plasma homocysteine coupled with diabetes cause a more dramatic alteration of retinal phenotype than elevated homocysteine or diabetes alone and suggest that diabetes accelerates the retinal neuronal death in hyperhomocysteinemic mice.
高同型半胱氨酸血症与视觉功能障碍有关。我们最近报道了内源性高同型半胱氨酸血症小鼠,由于胱硫氨酸-β-合成酶(cbs)基因突变,随着同型半胱氨酸水平的升高,视网膜神经节细胞(RGC)层和其他视网膜层的神经元丢失。一些临床研究暗示高同型半胱氨酸血症与糖尿病视网膜病变的发病机制有关,而糖尿病视网膜病变也以RGC丢失为特征。本研究使用cbs(+/-)小鼠来确定糖尿病患者血浆同型半胱氨酸的适度升高是否会加速神经元细胞的损失。用链脲佐菌素诱导3周龄cbs(+/-)和野生型小鼠发生糖尿病(DB);研究四组小鼠:DB - cbs(+/-);非数据库cbs (+ / -);DB cbs (+ / +);非数据库cbs(+ / +)。一组糖尿病cbs(+/-)小鼠维持高蛋氨酸饮食(HMD, 0.5%蛋氨酸饮用水)以略微增加血浆同型半胱氨酸。在糖尿病发病后5周、10周和15周取眼;视网膜冷冻切片通过光学显微镜检查,并进行系统的形态计量学分析。与年龄匹配的非糖尿病cbs(+/-)和野生型对照(10.0±0.5 vs 14.9±0.5和15.8±0.6细胞/100µm视网膜长度)相比,糖尿病cbs(+/-)在5周时的RGCs显著减少。糖尿病发病后15周,DB/高同型半胱氨酸组的视网膜与对照组有显著差异,包括RGCS减少,内核层和丛状层厚度减少。血浆同型半胱氨酸的适度升高与糖尿病合并引起的视网膜表型改变比同型半胱氨酸升高或糖尿病单独引起的视网膜表型改变更显著,这表明糖尿病加速了高同型半胱氨酸血症小鼠的视网膜神经元死亡。
{"title":"Diabetes Accelerates Retinal Neuronal Cell Death In A Mouse Model of Endogenous Hyperhomocysteinemia.","authors":"Preethi S Ganapathy, Penny Roon, Tracy K V E Moister, Barbara Mysona, Sylvia B Smith","doi":"10.4137/oed.s2855","DOIUrl":"https://doi.org/10.4137/oed.s2855","url":null,"abstract":"<p><p>Hyperhomocysteinemia has been implicated in visual dysfunction. We reported recently that mice with endogenous hyperhomocysteinemia, due to mutation of the cystathionine-β-synthase (cbs) gene, demonstrate loss of neurons in the retinal ganglion cell (RGC) layer and other retinal layers as homocysteine levels increase. Some clinical studies implicate hyperhomocysteinemia in the pathogenesis of diabetic retinopathy, which is also characterized by RGC loss. The present study used cbs(+/-) mice to determine whether modest elevation of plasma homocysteine, in the presence of diabetes, accelerates neuronal cell loss. Diabetes (DB) was induced in 3 wk old cbs(+/-) and wildtype mice using streptozotocin; four groups of mice were studied: DB cbs(+/-); non-DB cbs(+/-); DB cbs(+/+); non-DB cbs(+/+). One group of diabetic cbs(+/-) mice was maintained on a high methionine diet (HMD, 0.5% methionine drinking water) to increase plasma homocysteine slightly. Eyes were harvested at 5, 10 and 15 weeks post-onset of diabetes; retinal cryosections were examined by light microscopy and subjected to systematic morphometric analysis. Diabetic cbs(+/-) had significantly fewer RGCs at 5 weeks compared to age-matched, non-diabetic cbs(+/-) and wildtype controls (10.0 ± 0.5 versus 14.9 ± 0.5 and 15.8 ± 0.6 cells/100 µm retina length, respectively). Significant differences in retinas of DB/high homocysteine versus controls were obtained 15 wks post-onset of diabetes including fewer RGCS and decreased thickness of inner nuclear and plexiform layers. Moderate increases in plasma homocysteine coupled with diabetes cause a more dramatic alteration of retinal phenotype than elevated homocysteine or diabetes alone and suggest that diabetes accelerates the retinal neuronal death in hyperhomocysteinemic mice.</p>","PeriodicalId":74362,"journal":{"name":"Ophthalmology and eye diseases","volume":"1 ","pages":"3-11"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4137/oed.s2855","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28935424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2009-01-01DOI: 10.1177/117917210900100001
D. J. Cameron
I am pleased to announce the launch of Ophthalmology and Eye Diseases—a new peer reviewed open access journal published by Libertas Academica. Ophthalmology and Eye Diseases is an open access, peer reviewed journal covering all aspects of ophthalmology and vision science, especially the prevention, diagnosis and management of disorders of the eye. Related pathophysiology, genetics and epidemiology are also included. Articles describing clinical and/or basic research fi ndings are equally encouraged contributing to a broad readership and facilitating new ideas and approaches to vision related studies both in the clinic and the lab. The journal will be competing head-on with a number of existing subscription-based journals. However, there is clearly a niche for Ophthalmology and Eye Diseases in that all articles will be accessible without any access boundaries to Internet users throughout the world. Another major benefi t is that any vision scientist can contribute, not only those in major institutions. These freedoms are coupled with rigorous, fair and prompt standards of peer review. Ophthalmology and Eye Diseases is published exclusively online. Articles will follow a consistent format so that the visual impact will be high and equal to that of the best hardcopy publications. In contrast to paper-based journals, however, the electronic format allows the full use of digital technologies and permits the inclusion of large data sets, links to other web pages, animations, slide shows, video clips and unlimited colour, all at no additional charge. Open access means that all articles are freely available to everyone, worldwide, and at no cost to the reader. Authors retain copyright of their work and can grant anyone the right to reproduce and disseminate it, provided that the article is correctly cited and no errors are introduced, under the Creative Commons " CC-BY " licence. In hardcopy journals, the costs of publication are met by subscriptions, paid by the reader. In Ophthalmology and Eye Diseases, as in other open access journals, these costs are borne by the author in the form of a publication processing fee. Many grant-awarding bodies recognise the value of open access publishing by allowing their funds to be used for publication processing fees. Fee waivers and discounts are available on a case-by-case basis, and we will make every effort to ensure that lack of funds does not impede the overall objective of publishing the best science, irrespective of authorship or country of origin. I do not foresee that …
我很高兴地宣布,由Libertas Academica出版的一份新的同行评议的开放获取期刊《眼科学与眼病》(Ophthalmology and Eye diseases)即将面世。《眼科学与眼病》是一本开放获取、同行评审的期刊,涵盖了眼科学和视觉科学的各个方面,特别是眼睛疾病的预防、诊断和管理。相关的病理生理学,遗传学和流行病学也包括在内。描述临床和/或基础研究结果的文章同样受到鼓励,有助于广泛的读者群,并促进临床和实验室视觉相关研究的新想法和新方法。该期刊将与一些现有的基于订阅的期刊展开正面竞争。然而,《眼科学与眼病》显然有一个利基市场,因为全世界的互联网用户都可以无障碍地访问所有文章。另一个主要的好处是,任何视觉科学家都可以做出贡献,而不仅仅是那些主要机构的科学家。这些自由与严格、公平和及时的同行评议标准相结合。《眼科学与眼病》仅在线出版。文章将遵循一致的格式,使视觉影响将是高的,等于最好的硬拷贝出版物。然而,与纸质期刊相比,电子格式允许充分利用数字技术,并允许包含大型数据集、到其他网页的链接、动画、幻灯片、视频剪辑和无限颜色,所有这些都不需要额外收费。开放获取意味着所有的文章都可以免费提供给全世界的每个人,而且对读者来说是免费的。在知识共享“CC-BY”许可下,作者保留其作品的版权,并可以授予任何人复制和传播该作品的权利,前提是文章被正确引用且没有引入错误。在纸质期刊中,出版成本由订阅支付,由读者支付。在《眼科学与眼病》中,与其他开放获取期刊一样,这些费用以出版处理费的形式由作者承担。许多资助机构承认开放获取出版的价值,允许将其资金用于出版处理费。我们将根据具体情况提供费用减免和折扣,并且我们将尽一切努力确保资金的缺乏不会妨碍发表最佳科学的总体目标,无论作者身份或原产国如何。我不认为……
{"title":"Introductory Editorial","authors":"D. J. Cameron","doi":"10.1177/117917210900100001","DOIUrl":"https://doi.org/10.1177/117917210900100001","url":null,"abstract":"I am pleased to announce the launch of Ophthalmology and Eye Diseases—a new peer reviewed open access journal published by Libertas Academica. Ophthalmology and Eye Diseases is an open access, peer reviewed journal covering all aspects of ophthalmology and vision science, especially the prevention, diagnosis and management of disorders of the eye. Related pathophysiology, genetics and epidemiology are also included. Articles describing clinical and/or basic research fi ndings are equally encouraged contributing to a broad readership and facilitating new ideas and approaches to vision related studies both in the clinic and the lab. The journal will be competing head-on with a number of existing subscription-based journals. However, there is clearly a niche for Ophthalmology and Eye Diseases in that all articles will be accessible without any access boundaries to Internet users throughout the world. Another major benefi t is that any vision scientist can contribute, not only those in major institutions. These freedoms are coupled with rigorous, fair and prompt standards of peer review. Ophthalmology and Eye Diseases is published exclusively online. Articles will follow a consistent format so that the visual impact will be high and equal to that of the best hardcopy publications. In contrast to paper-based journals, however, the electronic format allows the full use of digital technologies and permits the inclusion of large data sets, links to other web pages, animations, slide shows, video clips and unlimited colour, all at no additional charge. Open access means that all articles are freely available to everyone, worldwide, and at no cost to the reader. Authors retain copyright of their work and can grant anyone the right to reproduce and disseminate it, provided that the article is correctly cited and no errors are introduced, under the Creative Commons \" CC-BY \" licence. In hardcopy journals, the costs of publication are met by subscriptions, paid by the reader. In Ophthalmology and Eye Diseases, as in other open access journals, these costs are borne by the author in the form of a publication processing fee. Many grant-awarding bodies recognise the value of open access publishing by allowing their funds to be used for publication processing fees. Fee waivers and discounts are available on a case-by-case basis, and we will make every effort to ensure that lack of funds does not impede the overall objective of publishing the best science, irrespective of authorship or country of origin. I do not foresee that …","PeriodicalId":74362,"journal":{"name":"Ophthalmology and eye diseases","volume":"1 1","pages":"1 - 1"},"PeriodicalIF":0.0,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/117917210900100001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"65350294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}